Brittney M Cox1, Brandon S Bentzley2, Helaina Regen-Tuero2, Ronald E See3, Carmela M Reichel2, Gary Aston-Jones4. 1. Department of Neurosciences, Medical University of South Carolina, Charleston, South Carolina. Electronic address: brittney.cox@uci.edu. 2. Department of Neurosciences, Medical University of South Carolina, Charleston, South Carolina. 3. Department of Neurosciences, Medical University of South Carolina, Charleston, South Carolina; Department of Psychology, Westmont College, Santa Barbara, California. 4. Department of Neurosciences, Medical University of South Carolina, Charleston, South Carolina; Brain Health Institute, Rutgers University/Rutgers Biomedical and Health Sciences, Piscataway, New Jersey.
Abstract
BACKGROUND: Evidence indicates that oxytocin, an endogenous peptide well known for its role in social behaviors, childbirth, and lactation, is a promising addiction pharmacotherapy. We employed a within-session behavioral-economic (BE) procedure in rats to examine oxytocin as a pharmacotherapy for methamphetamine (meth) addiction. The BE paradigm was modeled after BE procedures used to assess motivation for drugs in humans with addiction. The same BE variables assessed across species have been shown to predict later relapse behavior. Thus, the translational potential of preclinical BE studies is particularly strong. METHODS: We tested the effects of systemic and microinfused oxytocin on demand for self-administered intravenous meth and reinstatement of extinguished meth seeking in male and female rats using a BE paradigm. Correlations between meth demand and meth seeking were assessed. RESULTS: Female rats showed greater demand (i.e., motivation) for meth compared with male rats. In both male and female rats, meth demand predicted reinstatement of meth seeking, and systemic oxytocin decreased demand for meth and attenuated reinstatement to meth seeking. Oxytocin was most effective at decreasing meth demand and seeking in rats with the strongest motivation for drug. Finally, these effects of systemic oxytocin were mediated by actions in the nucleus accumbens. CONCLUSIONS: Oxytocin decreases meth demand and seeking in both sexes, and these effects depend on oxytocin signaling in the nucleus accumbens. Overall, these data indicate that development of oxytocin-based therapies may be a promising treatment approach for meth addiction in humans.
BACKGROUND: Evidence indicates that oxytocin, an endogenous peptide well known for its role in social behaviors, childbirth, and lactation, is a promising addiction pharmacotherapy. We employed a within-session behavioral-economic (BE) procedure in rats to examine oxytocin as a pharmacotherapy for methamphetamine (meth) addiction. The BE paradigm was modeled after BE procedures used to assess motivation for drugs in humans with addiction. The same BE variables assessed across species have been shown to predict later relapse behavior. Thus, the translational potential of preclinical BE studies is particularly strong. METHODS: We tested the effects of systemic and microinfused oxytocin on demand for self-administered intravenous meth and reinstatement of extinguished meth seeking in male and female rats using a BE paradigm. Correlations between meth demand and meth seeking were assessed. RESULTS: Female rats showed greater demand (i.e., motivation) for meth compared with male rats. In both male and female rats, meth demand predicted reinstatement of meth seeking, and systemic oxytocin decreased demand for meth and attenuated reinstatement to meth seeking. Oxytocin was most effective at decreasing meth demand and seeking in rats with the strongest motivation for drug. Finally, these effects of systemic oxytocin were mediated by actions in the nucleus accumbens. CONCLUSIONS:Oxytocin decreases meth demand and seeking in both sexes, and these effects depend on oxytocin signaling in the nucleus accumbens. Overall, these data indicate that development of oxytocin-based therapies may be a promising treatment approach for meth addiction in humans.
Authors: Dean S Carson; Glenn E Hunt; Adam J Guastella; Lachlan Barber; Jennifer L Cornish; Jonathon C Arnold; Aurelie A Boucher; Iain S McGregor Journal: Addict Biol Date: 2010-08-23 Impact factor: 4.280
Authors: Chad M Galuska; Kelly M Banna; Lena Vaughn Willse; Noushin Yahyavi-Firouz-Abadi; Ronald E See Journal: Behav Pharmacol Date: 2011-08 Impact factor: 2.293
Authors: Helena J V Rutherford; Sarah K Williams; Sheryl Moy; Linda C Mayes; Josephine M Johns Journal: Front Psychiatry Date: 2011-07-06 Impact factor: 4.157
Authors: Gregory L Powell; Gabriella Cabrera-Brown; Mark D Namba; Janet L Neisewander; Julie A Marusich; Joshua S Beckmann; Cassandra D Gipson Journal: Drug Alcohol Depend Date: 2019-06-20 Impact factor: 4.492
Authors: Elizabeth A Crummy; Elizabeth A Donckels; Britahny M Baskin; Brandon S Bentzley; Susan M Ferguson Journal: Psychopharmacology (Berl) Date: 2019-08-28 Impact factor: 4.530